Drug Profile
Research programme: small molecule therapeutics - Abilita Bio/X-Chem
Latest Information Update: 07 Jun 2023
Price :
$50
*
At a glance
- Originator Abilita Bio; X-Chem
- Developer Abilita Therapeutics; X-Chem
- Class Small molecules
- Mechanism of Action G protein-coupled receptor modulators; Ion channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified